Reductase inhibitor therapy of hypercholesterolemia.
作者信息
Kreisberg R A
机构信息
Department of Medicine, University of Alabama, Birmingham.
出版信息
Trans Am Clin Climatol Assoc. 1991;102:153-63; discussion 163-5.
Abstract
摘要
相似文献
1
Reductase inhibitor therapy of hypercholesterolemia.
Trans Am Clin Climatol Assoc. 1991;102:153-63; discussion 163-5.
2
Worldwide experience with simvastatin/lovastatin.
Eur Heart J. 1992 Jul;13 Suppl B:21-2. doi: 10.1093/eurheartj/13.suppl_b.21.
3
Statin therapy in clinical practice: new developments.
Curr Opin Lipidol. 1995 Oct;6(5):254-5.
4
[Simvastatin in the treatment of hypercholesterolemia].
Clin Ter. 1991 Jun 15;137(5):333-7.
5
6
[Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary hypercholesterolemia].
Schweiz Med Wochenschr. 1989 Dec 2;119(48):1719-23.
7
Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease.
N Z Med J. 1990 Feb 14;103(883):41-3.
8
[Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of the hepatic cytochrome P450 enzyme system activity].
Schweiz Med Wochenschr. 1995 Jul 11;125(27-28):1342-6.
9
HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation.
Transplant Proc. 1993 Feb;25(1 Pt 2):1043-6.
10
Marked improvement in cholestasis and hypercholesterolemia with simvastatin in a patient with primary biliary cirrhosis.
Am J Gastroenterol. 1995 Jul;90(7):1187-8.
引用本文的文献
1
Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers.
Cell Death Dis. 2017 Jan 19;8(1):e2564. doi: 10.1038/cddis.2016.418.
本文引用的文献
1
Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen.
N Engl J Med. 1981 Jan 29;304(5):251-8. doi: 10.1056/NEJM198101293040502.
2
Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia.
Lancet. 1972 Sep 9;2(7776):506-9. doi: 10.1016/s0140-6736(72)91905-8.
3
Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia.
Ann Intern Med. 1987 Nov;107(5):616-23. doi: 10.7326/0003-4819-107-5-616.
4
Cholesterol and mortality. 30 years of follow-up from the Framingham study.
JAMA. 1987 Apr 24;257(16):2176-80. doi: 10.1001/jama.257.16.2176.
5
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
N Engl J Med. 1987 Nov 12;317(20):1237-45. doi: 10.1056/NEJM198711123172001.
6
Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.
JAMA. 1987 Jun 19;257(23):3233-40.
7
Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin.
J Clin Endocrinol Metab. 1987 Sep;65(3):546-50. doi: 10.1210/jcem-65-3-546.
8
The effect of mevinolin on steroidogenesis in patients with defects in the low density lipoprotein receptor pathway.
J Clin Endocrinol Metab. 1987 Mar;64(3):531-5. doi: 10.1210/jcem-64-3-531.
9
Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia.
Circulation. 1989 Mar;79(3):590-6. doi: 10.1161/01.cir.79.3.590.
10
Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
Arch Intern Med. 1990 Feb;150(2):341-5.
Zotero 插件